Maryland ? A “pink pill” to boost women’s sex drive remains elusive after a decade of searching by some of the world’s biggest drugmakers.

A panel of health experts on Friday rejected the latest offering submitted for federal approval: an antidepressant drug that failed to increase sexual desire in two studies.

The Food and Drug Administration’s panel of reproductive advisers voted unanimously that the benefits of the pill from Boehringer Ingelheim did not outweigh side effects, including fatigue, depression and fainting spells.

The FDA will make its own decision on the drug in coming months, though it usually follows the advice of its panelists.

The drug flibanerin, which acts on serotonin and other brain chemicals, was originally studied as a depression therapy, but then repurposed as a libido pill after women reported unusually high levels of sexual satisfaction.